Daniels Ronald J's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Dec 30, 2021
- Accession no.
- 0000899243-21-050130
- Filed
- Dec 30, 2021
- Trade date
- Dec 28-30, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $298.7K. Open-market sales total $150.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Daniels Ronald JCIK 0001164475 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 28, 2021 | Common Stock | PPurchaseAcquired | +11,745 | $12.73F2 | +$149,513.85 | 11,745 | Direct | |
| Dec 28, 2021 | Common Stock | SSaleDisposed | −11,745 | $12.80F3 | −$150,336 | 0 | Direct | |
| Dec 30, 2021 | Common Stock | PPurchaseAcquired | +10,402 | $14.34 | +$149,164.68 | 10,402 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $12.7275 to $12.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $12.79 to $12.82 per share.
Referenced by the price of 1 transaction in Table I.